EA015559B1 - ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH - Google Patents

ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH Download PDF

Info

Publication number
EA015559B1
EA015559B1 EA200970582A EA200970582A EA015559B1 EA 015559 B1 EA015559 B1 EA 015559B1 EA 200970582 A EA200970582 A EA 200970582A EA 200970582 A EA200970582 A EA 200970582A EA 015559 B1 EA015559 B1 EA 015559B1
Authority
EA
Eurasian Patent Office
Prior art keywords
chlorophenyl
pyridin
mmol
yloxy
thiazolo
Prior art date
Application number
EA200970582A
Other languages
English (en)
Russian (ru)
Other versions
EA200970582A1 (ru
Inventor
Кевин Мэттью Гардинир
Дэвид Джозеф Гармен
Эрик Джеймс Хембр
Майкл Брунавс
Хелен Джейн Секереш
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39204735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA015559(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200970582A1 publication Critical patent/EA200970582A1/ru
Publication of EA015559B1 publication Critical patent/EA015559B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
EA200970582A 2006-12-14 2007-11-15 ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH EA015559B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87001106P 2006-12-14 2006-12-14
PCT/US2007/084812 WO2008076562A1 (en) 2006-12-14 2007-11-15 5- [4- (azetidin-3-yl0xy) -phenyl] -2-phenyl-5h-thiaz0l0 [5,4-c] pyridin-4-0ne derivatives and their use as mch receptor antagonists

Publications (2)

Publication Number Publication Date
EA200970582A1 EA200970582A1 (ru) 2010-02-26
EA015559B1 true EA015559B1 (ru) 2011-08-30

Family

ID=39204735

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970582A EA015559B1 (ru) 2006-12-14 2007-11-15 ПРОИЗВОДНЫЕ 5-[4-(АЗЕТИДИН-3-ИЛОКСИ)ФЕНИЛ]-2-ФЕНИЛ-5H-ТИАЗОЛО[5,4-c]ПИРИДИН-4-ОНА И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ РЕЦЕПТОРОВ MCH

Country Status (16)

Country Link
US (1) US8049013B2 (cg-RX-API-DMAC7.html)
EP (1) EP2089397B1 (cg-RX-API-DMAC7.html)
JP (1) JP5269804B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090082484A (cg-RX-API-DMAC7.html)
CN (1) CN101558075A (cg-RX-API-DMAC7.html)
AR (1) AR064127A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007334171A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0721086A2 (cg-RX-API-DMAC7.html)
CA (1) CA2671765A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007003480A1 (cg-RX-API-DMAC7.html)
EA (1) EA015559B1 (cg-RX-API-DMAC7.html)
ES (1) ES2392276T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009006319A (cg-RX-API-DMAC7.html)
PE (1) PE20081572A1 (cg-RX-API-DMAC7.html)
TW (1) TW200831082A (cg-RX-API-DMAC7.html)
WO (1) WO2008076562A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
AU2010332819B2 (en) 2009-12-18 2014-02-27 Janssen Pharmaceutica Nv Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
EP2513117B1 (en) 2009-12-18 2013-08-28 Janssen Pharmaceutica, N.V. Bicyclic thiazoles as allosteric modulators of mglur5 receptors
EA201291384A1 (ru) * 2010-07-06 2013-07-30 Астразенека Аб Терапевтические агенты 976
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014115801A1 (ja) * 2013-01-25 2014-07-31 セントラル硝子株式会社 α,α-ジフルオロアセトアルデヒドの製造方法
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
CN116082225A (zh) * 2016-08-08 2023-05-09 北京康蒂尼药业股份有限公司 一种羟尼酮的制备方法
CN107698498A (zh) * 2016-08-08 2018-02-16 罗楹 一种羟尼酮的制备方法
CN108997138A (zh) * 2018-08-17 2018-12-14 济南和润化工科技有限公司 一种无溶剂催化氢化法生产对氟苯胺的方法
US20260152484A1 (en) * 2021-11-09 2026-06-04 Vigil Neuroscience, Inc. Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033476A1 (en) * 2001-10-15 2003-04-24 Smithkline Beecham Plc Pyrimidinones as melanin concentrating hormone receptor 1
WO2006066174A1 (en) * 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033476A1 (en) * 2001-10-15 2003-04-24 Smithkline Beecham Plc Pyrimidinones as melanin concentrating hormone receptor 1
WO2006066174A1 (en) * 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WITTY ET AL.: "Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 16, no. 18, 15 September 2006 (2006-09-15), pages 4872-4878, XP005594980, ISSN: 0960-894X, the whole document, in particular, (i) page 4875, column 2, last paragraph - page 4876, column 1, first paragraph, and (ii) page 4876, table 1, compounds 1b and 8a *

Also Published As

Publication number Publication date
WO2008076562A1 (en) 2008-06-26
JP5269804B2 (ja) 2013-08-21
CN101558075A (zh) 2009-10-14
EP2089397A1 (en) 2009-08-19
CA2671765A1 (en) 2008-06-26
TW200831082A (en) 2008-08-01
CL2007003480A1 (es) 2008-07-11
EP2089397B1 (en) 2012-08-29
MX2009006319A (es) 2009-12-14
JP2010513292A (ja) 2010-04-30
KR20090082484A (ko) 2009-07-30
AU2007334171A1 (en) 2008-06-26
BRPI0721086A2 (pt) 2014-02-25
US8049013B2 (en) 2011-11-01
ES2392276T3 (es) 2012-12-07
AR064127A1 (es) 2009-03-11
EA200970582A1 (ru) 2010-02-26
PE20081572A1 (es) 2008-12-27
US20100069352A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
ES2392276T3 (es) Derivados de 5-[4-(azetidin-3-iloxi)-fenil]-2-fenil-5H-tiazolo[5,4-c]piridin-4-ona y su uso como antagonistas del receptor de MCH
TWI877697B (zh) 作為parp7抑制劑的嗒酮
RU2695664C1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
JP2021185177A (ja) オキサジアゼピノン誘導体及びb型肝炎感染症の治療におけるその使用
RU2696270C1 (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf
JP4459807B2 (ja) テトラヒドロピラニルシクロペンチルテトラヒドロイソキノリン系のケモカイン受容体活性調節剤
JP2683479B2 (ja) ヒドロピリジン誘導体
RU2678305C1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
RU2677699C1 (ru) Производные имидазотриазина в качестве модуляторов активности tnf
JP6026441B2 (ja) キナーゼ阻害剤としてのアミノキノリン
CA2409743C (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
EA015127B1 (ru) Антагонисты мсн-рецепторов
BG107285A (bg) Бета - карболинови производни като инхибитори на фосфодиестераза
JP4734119B2 (ja) インダゾール化合物及びその医薬用途
KR20130098269A (ko) 테트라히드로카르볼린 유도체
AU2010202008A1 (en) Substituted 2,4-dihydro-pyrrolo (3,4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
RU2683940C1 (ru) Производные имидазотиазола в качестве модуляторов активности tnf
KR20020015030A (ko) cGMP 포스포디에스테라제의 접합된 피리도피리다진억제제
JPWO1995018130A1 (ja) 3環性ベンゾアゼピンおよびベンゾチアゼピン誘導体
US20130053372A1 (en) 5-ht receptor modulators
KR20050099525A (ko) 피롤로트리아진 키나제 억제제의 제조 방법
US20080139588A1 (en) Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
ES2887674T3 (es) 1-Arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
JP7611900B2 (ja) 縮合複素環化合物
JPH06336484A (ja) 二環性複素環化合物

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU